Alberto Bessudo, MD
Hematology & Oncology · Encinitas, CANPI 1003888074
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 19.0%. Reporting peaked in 2024 at $13,587 and has fallen 71.1% since, to $3,924 in 2025.
Across 1,097 payments — averaging $49.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$10K
- Daiichi Sankyo Inc.$6K
- Bayer$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Karyopharm Therapeutics Inc.$2K
- Epizyme, Inc.$2K
- plus $24K from 54 others
Across 713 payments — averaging $5527.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.7M
- Pfizer$649K
- Tesaro, Inc.$615K
- GSK$380K
- Astrazeneca UK Limited$227K
- Morphosys AG$55K
- plus $298K from 15 others
What the payments were for
- Consulting fees$20,89038%
- Speaking & faculty fees$6,00011%
- Travel & lodging$9172%
- Food & beverage$26,36448%
- Education$4201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SARCLISA$9,012
- Enhertu$5,885
- Nubeqa$3,857
- TAZVERIK$2,373
- XPOVIO$2,250
- FIRDAPSE$1,673
- MONJUVI$1,440
- SOMATULINE DEPOT$491
- ONIVYDE$491
- FOUNDATIONACT$300
- FOUNDATIONFOCUS$300
- FOUNDATIONONE CDX$300
- FOUNDATIONONE HEME$300
- FOUNDATIONONE$300
- LUMAKRAS$125
- Trodelvy$124
- BESREMI$123
- GAVRETO$123
- XGEVA$122
- JEVTANA$118
How this compares
$54,591 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 63 | $1,070,533 |
| JakafiRuxolitinib Phosphate | 60 | $982,548 |
| PomalystPomalidomide | 28 | $628,150 |
| XtandiEnzalutamide | 36 | $501,404 |
| Lenalidomide | 25 | $375,645 |
| RevlimidLenalidomide | 19 | $326,034 |
| ImbruvicaIbrutinib | 13 | $210,805 |
| VenclextaVenetoclax | 20 | $185,669 |
| CalquenceAcalabrutinib Maleate | 12 | $163,099 |
| EliquisApixaban | 47 | $26,171 |
| XareltoRivaroxaban | 14 | $14,862 |
| Anagrelide Hcl | 20 | $11,590 |
| Hydroxyurea | 28 | $579 |
| Bicalutamide | 21 | $572 |
| Ondansetron OdtOndansetron | 27 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $1,705 | $1,233,63275 claims |
| Incyte CorporationJakafi | $323 | $982,54860 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $3,343 | $628,15028 claims |
| Astellas Pharma US IncXtandi | $272 | $501,40436 claims |
| Bristol Myers SquibbRevlimid | $600 | $326,03419 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $630 | $210,80513 claims |
| AbbVieVenclexta | $648 | $185,66920 claims |
| PfizerEliquis | $1,249 | $26,17147 claims |
| Johnson & JohnsonXarelto | $769 | $14,86214 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $67 | $16516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Encinitas
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.